ATF3 and nasopharyngeal carcinoma: Zhu et al. found that the MRVI1-AS1/ATF3 signalling pathway could increase paclitaxel chemosensitivity by modulating the Hippo-TAZ signalling pathway in nasopharyngeal cancer (21).